Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26530491 | 0.92 | CYP11B1 (0.41) | HDAC6HDAC1CYP11B1CYP11B2 | |
| SCHEMBL26529785 | 0.92 | HDAC6 (0.46) | HDAC6HDAC1 | |
| SCHEMBL26530401 | 0.89 | HDAC6 (0.42) | HDAC6HDAC1 | |
| SCHEMBL26529863 | 0.84 | HDAC6 (0.44) | HDAC6HDAC1CYP11B1CYP11B2 | |
| SCHEMBL26530404 | 0.83 | HDAC6 (0.46) | HDAC6 | |
| SCHEMBL26530481 | 0.83 | HDAC6 (0.43) | HDAC6HDAC1 | |
| SCHEMBL26530457 | 0.83 | HDAC6 (0.43) | HDAC6 | |
| SCHEMBL26530420 | 0.83 | HDAC6 (0.46) | HDAC6CYP11B1CYP11B2 | |
| SCHEMBL26530471 | 0.82 | HDAC6 (0.41) | HDAC6HDAC1 | |
| SCHEMBL26530397 | 0.82 | HDAC6 (0.52) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885PLA2G7 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.